Final Agenda

Cambridge Healthtech Institute's

Ninth Annual

World Pharmaceutical Congress

REGISTER BY March 12 & SAVE up to $350!

June 15-17, 2010
Sheraton Philadelphia City Center
Philadelphia, Pennsylvania

Preclinical Developments to Better Predict Outcomes

Drug Discovery Innovation Summit

- Targeting Pain with Novel Therapeutics
- Successful Targeting of Alzheimer's Disease

Drug Safety Summit

- Monitoring Cardiotoxicity and Drug Safety
- New Tools for Detecting Nephrotoxicity
- Early Assessments for Predicting Hepatotoxicity

Screening and Imaging Summit

- Evaluating Novel Technologies for Cell Based Screening
- Integrating *in vivo* Molecular Imaging in Drug Discovery & Development
- Pharmacology Driven Assays for GPCRs & Ion Channels

Conference Short Courses - June 14 & 16

Reactive Metabolites in Drug Discovery and Development

Animal Models of Pain: Progress and Challenges

Translating Safety Biomarkers from the Lab to the Clinic

Use of Stem Cells for Safety Screening

Dealing with the Blood-Brain Barrier

Safety Concerns for Biological Drugs

Mechanistic Insights into Cardiotoxicity

Mechanistic Insights into Hepatotoxicity

Event Features

- **Plenary Keynote Panel**
- **Interactive Breakout Discussion Groups**
- **Access to Concurrent Tracks**
- **Dedicated Exhibit Hall and Scientific Poster Viewing Hours**
- **Over 500 International Participants**
- **10 Short Courses**

Corporate Sponsors:

Lead Sponsoring Publications:

Sponsoring Organization:

Cambridge Healthtech Institute, 250 First Avenue, Suite 300, Needham, Massachusetts 02494
Telephone: 781-972-5400 or toll-free in the U.S. 888-999-6288 • Fax: 781-972-5425 • www.healthtech.com

WorldPharmaCongress.com

Conference-at-a-Glance

MONDAY, JUNE 14

8:00am-9:00am	Morning Coffee
8:00-9:00am	Pre-Conference Short Course Registration
9:00am-12:00pm	Morning Short Courses
1:00-2:00pm	Pre-Conference Short Course Registration
2:00-5:00pm	Afternoon Short Courses
2:00-5:00pm	Main Conference Pre-Registration

TUESDAY, JUNE 15

7:15am-6:00pm	Registration Open
7:15-8:15am	Morning Coffee
8:15-9:55am	Concurrent Tracks
9:55-10:25am	Networking Coffee Break
10:25-11:55am	Concurrent Tracks
11:55am-12:55pm	Luncheon Presentation *(Sponsorship Opportunity Available)* or Lunch on Your Own
12:55-1:30pm	Session Break
1:30-3:05pm	Concurrent Tracks
3:05-3:35pm	Sponsored Presentations *(Opportunities Available)*
3:35-4:15pm	Grand Opening Refreshment Break in the Exhibit Hall
4:15-5:45pm	Plenary Keynote Panel
5:45-6:45pm	Happy Hour in the Exhibit Hall
6:45pm	Close of Day

WEDNESDAY, JUNE 16

7:30am-5:30pm	Registration Open
7:30-8:30am	Continental Breakfast Breakout Discussions
8:30-9:40am	Concurrent Tracks
9:40-10:10am	Sponsored Presentations *(Opportunity Available)*
10:10-10:50am	Networking Coffee Break in the Exhibit Hall
10:50am-12:20pm	Concurrent Tracks
12:20pm	Close of First Set of Conferences
12:20-1:55pm	Enjoy Lunch on your Own
1:55-3:00pm	Concurrent Tracks- Second Set of Conferences
3:00-3:30pm	Sponsored Presentations *(Opportunity Available)*
3:30-4:30pm	Networking Refreshment Break in the Exhibit Hall
4:30-5:30pm	Concurrent Tracks
5:30pm	Close of Day

THURSDAY, JUNE 17

8:00am-4:00pm	Registration Open
8:00-8:30am	Morning Coffee
8:30-10:00am	Concurrent Tracks
10:00-10:45am	Networking Coffee Break in the Exhibit Hall
10:45-11:45am	Concurrent Tracks
11:45am-12:45pm	Luncheon Presentation *(Sponsorship Opportunity Available)* or Lunch on Your Own
12:45-1:15pm	Session Break
1:15-2:25pm	Concurrent Tracks
2:25-3:05pm	Ice Cream Refreshment Break in the Exhibit Hall *(Last Chance for Exhibit & Poster Viewing)*
3:05-4:35pm	Concurrent Tracks
4:35pm	Close of Conference

CHI's ***World Pharmaceutical Congress*** encompasses a broad spectrum of topics that are very important to scientists in the pharmaceutical and biotechnology industry. This year's event focuses mainly on the pre-clinical aspects of drug discovery and development and consists of three separate summits, each featuring various tracks. The topics offer a broad-based perspective on what's going on in the field, tackling issues relevant to chemists, biologists, pharmacologists, toxicologists and clinicians alike. Each track features presentations, interactive panels and technology talks that cover the very latest on the topic, both on the scientific and the technical side. The ***World Pharmaceutical Congress*** also offers attendees and exhibitors ample opportunity to network, brain-storm and collaborate on various fronts.

Plenary Keynote Panel

TUESDAY, JUNE 15

4:15 - 5:45 pm Shifting Sands of Pharmaceutical Discovery

Panelists:

Chris L. Waller, Ph.D., Senior Director, HealthCare Informatics, Medical Business Technology, Pfizer, Inc.

Gary Peltz, M.D., Ph.D., Professor, Anesthesia, Stanford University

Marvin Bayne, Ph.D., Head of Discovery Technologies, Merck & Co.

Thomas Bocan, Ph.D., Senior Director, Head of Pre-Clinical BioImaging Center, Pfizer Global Research and Development, Pfizer, Inc.

Peggy Guzzie-Peck, Ph.D., DABT, Vice President, Head of Toxicology, Pathology & LAM, Johnson & Johnson, Pharma R&D

Key questions to be addressed:

- How does academic research impact pharma drug discovery?
- How does the creation of cross-pharma pre-competitive collaborations impact drug discovery, spanning chemistry, biology, and knowledge management?
- Adoption of new technologies, such as molecular imaging: Can it help drug discovery and how quickly?
- How effectively and efficiently can we collaborate to develop safer drugs?

Monday, June 14

MORNING COURSES 9:00 am – 12:00 pm

(SC1) Reactive Metabolites in Drug Discovery and Development-A Critical Examination of the Issues

You will obtain a perspective on the variety of factors necessary to make informed decisions regarding reactive metabolites.

- Analytical approaches to detect and characterize reactive metabolites
- Bioactivation pathways that lead to reactive metabolites
- Toxicophores and Structural Alerts
- Evidence linking reactive metabolites and Idiosyncratic drug toxicity
- Reactive metabolites and covalent protein binding

Course Instructor:
John C.L. Erve, Ph.D., DABT, Principal Research Scientist II, Drug Safety Metabolism, Wyeth Research

(SC2) Animal Models of Pain: Progress and Challenges

Due to frustration with translational progress, animal models of pain are currently being reconsidered. This course will cover:

- Implementation of classical models of acute, tonic and chronic pain
- Limitations of these classical models
- Refinement of classical models via a consideration of modulatory factors (sex, genetics, testing environment, social modulation)
- Development of new animal models (e.g., operant methods, spontaneous behaviors)

Course Instructor:
Jeffrey S. Mogil, Ph.D., E.P. Taylor Professor of Pain Studies, McGill University

(SC3) Translating Safety Biomarkers from the Lab to the Clinic

The course offers a unique and practical perspective for successfully translating the pre-clinical work done for testing and validating safety biomarkers to the clinic.

- Design and implementation of studies to identify new biomarkers
- Designing clinical studies to test and validate biomarkers
- Clinical methodologies for cost-effective and reliable decision-making
- Bridging the gap between pre-clinical and clinical findings
- Practical considerations when using biomarkers in the clinic
- Points to consider for a successful transfer from the lab to the clinic

Course Instructor:
Stephen Furlong, Ph.D., Safety Science Lead, U.S., Patient Safety, AstraZeneca
William B. Mattes, Ph.D., DABT, Independent Consultant, PharmPoint Consulting
J. Rick Turner, Ph.D., Senior Scientific Director, Cardiac Safety Services, Quintiles

QUINTILES

(SC4) Use of Stem Cells for Safety Screening

The course provides new insights into the use of embryonic and pluripotent stem cells for drug safety testing, especially cardiac safety.

- Differentiation of human stem cells into cardiac myocytes
- Comparison of electrophysiology and pharmacology
- Overcoming technical challenges related to working with stem cells
- Methodologies to maintain and use stem cells for predictive safety testing

Course Instructors:
Craig T. January, M.D., Ph.D., Professor, Medicine and Physiology, Division of Cardiovascular Medicine, University of Wisconsin-Madison
Timothy J. Kamp M.D., Ph.D., Professor of Medicine and Physiology and Director, Stem Cell and Regenerative Medicine, University of Wisconsin School of Medicine and Public Health
Dany Salvail, Ph.D., Director , Pharmacology, Cardiac Safety and Toxicity, IPS Therapeutique, Inc.
Steven L. Stice, Ph.D., Professor, Director, Regenerative Bioscience Center, University of Georgia

AFTERNOON COURSES 2:00 pm – 5:00 pm

(SC5) Dealing with the Blood-Brain Barrier

You will obtain a perspective on the variety of factors necessary to make informed decisions regarding blood-brain barrier.

- The physiological basis for the "barrier" nature of the BBB
- Experimental approaches (*in vitro*/*in vivo*) that are available for screening for brain penetration
- Medicinal chemistry perspective on *in vitro*/*in silico* approaches for optimizing CNS penetration
- Multi-parameter optimization (MPO) for CNS penetration
- *in vivo* examples where all these concepts are applied together, e.g., consideration of free fractions in various compartments in relation to *in vitro* pharmacology values
- Projecting human receptor occupancies considering species differences in affinity, free fraction
- Exposure targeting for biomarker studies

Course Instructors:
Douglas Spracklin, Ph.D., Director, Pharmacokinetics, Dynamics & Metabolism, Pfizer, Inc.
Christopher L. Shaffer, Ph.D., Associate Research Fellow, Pharmacokinetics, Dynamics & Metabolism, Pfizer, Inc.
Travis T. Wager, Ph.D., Associate Research Fellow, Neuroscience Discovery Medicinal Chemistry, Pfizer, Inc.

(SC6) Addressing Safety Concerns for Biological Drugs

The course offers guidance from experts in the field on what is being used and looked at for early safety assessments for biological molecules and how these early predictions are then being applied for clinical testing.

- Overview of challenges pertaining to the safety of biologics
- Tools, markers and assays for early safety predictions
- Assessing immunogenicity, PK/PD and off-target effects
- Regulatory guidelines and their interpretations
- Criteria for determining what needs to be tested and when

Course Instructors:
Gary Gintant, Ph.D., Senior Group Leader, Department of Integrative Pharmacology, Abbott Laboratories
Lauren Black, Ph.D., Senior Scientific Advisor, Charles River Laboratories
Noël Dybdal, Ph.D., D.V.M., Associate Director, Principal Scientist, Safety Assessment, Genentech, Inc.
Lisa Plitnick, Ph.D., Senior Investigator, Biologics Safety Assessment, Merck & Co. Inc.

(SC8) Mechanistic Insights into Cardiotoxicity

The course offers detailed information about some of the genetic and physiological factors that trigger cellular pathways leading to cardiac injury and failure.

- Genetics, physiology and risks in human heart failure
- Mechanisms underlying sex differences in ion channel expression and their role in arrhythmia phenotype
- Sex differences in the severity of ischemic injuries and in general, the effects of sex steroids in metabolic injuries

Course Instructors:
Barry London, M.D., Ph.D., Professor of Medicine and Chief, Division of Cardiology, University of Pittsburgh School of Medicine
Guy Salama, Ph.D., Department of Cell Biology and Physiology, University of Pittsburgh School of Medicine
Kenneth S. Korach, Ph.D., Director, Environmental Disease and Medicine Program; Chief, Laboratory of Reproductive and Developmental Toxicology, NIEHS/NIH

*Separate Registration Required

Short Courses*

Wednesday, June 16

6:00 – 9:00 pm *(Dinner will be served)*

(SC9) Mechanistic Insights into Hepatotoxicity

The course is designed for both pre-clinical and clinical scientists looking to better understand the mechanisms underlying drug-induced liver injury or DILI, to help in the development of early predictive technologies for hepatotoxicity including mechanism-based assays. It provides an overview of cellular pathways involved in:

- Mitochondrial dysfunction and Oxidative stress
- Inflammation
- Excessive generation of reactive metabolites
- Inhibition of bile salt efflux protein and involvement of hepatic transporters in drug-induced hepatotoxicity

Course Instructors:
Amit S. Kalgutkar, Ph.D., Research Fellow, Pharmacokinetics, Dynamics and Metabolism Department, Pfizer Global R&D
José E. Manautou, Ph.D., Associate Professor of Toxicology, Department of Pharmaceutical Sciences, University of Connecticut
Ivan Rusyn, M.D., Ph.D., Associate Professor of Environmental Science and Engineering, University of North Carolina
Yvonne Will, Ph.D., Associate Research Fellow, Compound Safety Prediction, Pfizer Global R&D

**Separate Registration Required*

Breakout Discussions

Wednesday, June 16

7:30 - 8:30 am CONTINENTAL BREAKFAST BREAKOUT DISCUSSIONS

TOPICS

Choosing the Right Criteria and Assays for Testing High-Risk Biologicals
Moderator: Noël Dybdal, Ph.D., D.V.M., Associate Director, Principal Scientist, Safety Assessment, Genentech, Inc.

Correlating *in vitro* Data With Clinical Outcomes
Moderator to be Announced

Evaluating New Tools for Assessing Preclinical Safety
Moderator: Gary Gintant, Ph.D., Senior Group Leader, Department of Integrative Pharmacology, Global Pharmaceutical Research & Development, Abbott Laboratories

GPCRs and Ligand Bias
Moderator: Lisa K. Minor, Ph.D., President, In Vitro Strategies, LLC

Increasing the Relevancy of Cell Based Assays
Moderator: Charles Lunn, Ph.D., Research Fellow, New Lead Discovery, Merck Research Laboratories

To Kill, or Not to Kill a Program
Moderator: Elizabeth A. Davenport, Ph.D., Manager, Cell-Based Assay Development, Department of Biological Reagents and Assay Development, GlaxoSmithKline

Animal Models in Pain
Moderator: Ed Bilsky, Ph.D., Professor of Pharmacology, COM; Director, Center of Excellence in the Neurosciences, University of New England

Ion Channels as Pain Targets
Moderator: Michael F. Jarvis, Ph.D., Vowiler Research Fellow, Associate Director, Neuroscience, Global Pharmaceutical Research & Development, Abbott

Pain Clinical Trials
Moderator: Linda Jett, MSN, Clinical Director, Drug Development, DARA BioSciences

Automated ECG Reading in Thorough QT/QTc and Other Trials: Current Thoughts
Moderator: J. Rick Turner, Ph.D., Senior Scientific Director, Cardiac Safety Services, Quintiles

The employment of automated algorithms for reading ECG intervals is receiving much current attention. There are strong opinions in favor and not in favor of this methodology. Attendees will be invited to share their experiences and thoughts.

Learning Objectives

- Understand the evolution of automated methodologies.
- Understand that all algorithms are not created equal.
- Become familiar with views on all sides concerning this methodology.

Third Annual

Targeting Pain with Novel Therapeutics

Leading the Chase to the Clinic

June 15-16

Recommended Short Courses*

Monday, June 14

9:00 am – 12:00 pm

(SC2) Animal Models of Pain: Progress and Challenges

(SC1) Reactive Metabolites in Drug Discovery and Development-A Critical Examination of the Issues

2:00 pm – 5:00 pm

(SC5) Dealing with the Blood-Brain Barrier

**Separate Registration Required; Please See Page 3 for Details.*

TUESDAY, JUNE, 15

7:15 am Registration and Morning Coffee

Anti NGF and TRK Inhibition

8:15 Chairperson's Opening Remarks
Ramana Sonty, Ph.D., Director, Neuroscience Program, Wyeth Pharmaceuticals

8:25 KEYNOTE ADDRESS

Antagonism of NGF-TrkA Signaling and the Relief of Musculoskeletal Pain
Pat Mantyh, Ph.D., J.D., Department of Pharmacology, University of Arizona College of Medicine

8:55 Inhibition of Nerve Growth Factor for Treatment of Pain: Going Beyond Traditional Analgesic Drugs?

Kenneth Verburg, Ph.D., Vice President, Development Head, Pfizer's Pain Portfolio, Pfizer, Inc.

9:25 Small Molecule Trk Inhibitors in Pre-Clinical Models of Pain
Steven W. Andrews, Ph.D., Associate Director, Drug Discovery, Array BioPharma, Inc.

9:55 Networking Coffee Break

Leading Edge Case Studies

10:25 CGRP and Migraine
David J. Hewitt, M.D., Senior Director, Clinical Neuroscience, Merck Research Laboratories

10:55 Translational Medicine in Pain Drug Development—Can NHP Models, Biomarkers for Proof of Mechanism and Patient Selection Improve Our Success Rate?
Hong Wan, Ph.D., Director, Translational Medicine, Pfizer, Inc.

11:25 Discovery of PF-04457845, a Highly Selective Urea FAAH Inhibitor that Reduces Inflammatory Pain
Douglas S. Johnson, Ph.D., Senior Principal Scientist, Medicinal Chemistry, Pfizer Global Research & Development

11:55 Luncheon Presentations *(Sponsorship Opportunities Available)* **or Lunch on Your Own**

Ion Channels and Pain

1:25 pm Chairperson's Remarks
Richard Lewis, Ph.D., CSO, Research & Development, Xenome Ltd.

1:35 KEYNOTE ADDRESS

Learning from Men on Fire: Sodium Channels and Human Pain
Stephen G. Waxman, M.D., Ph.D., Bridget Marie Flaherty Professor of Neurology, Neurobiology, and Pharmacology; Director, Center for Neuroscience & Regeneration/ Rehabilitation Research, Yale University School of Medicine

2:05 Selective Pharmacological Blockade of Sodium $Na_v1.8$ Channels Relieves Experimental Inflammatory and Neuropathic Pain
Michael F. Jarvis, Ph.D., Vowiler Research Fellow, Associate Director, Neuroscience, Global Pharmaceutical Research & Development , Abbott

2:35 Computational Genetics: Pain and Beyond

Gary Peltz, M.D., Ph.D., Professor, Anesthesia, Stanford University

3:05 Evaluation of the Antinociceptive Potential of Neu-P12, a New Drug Candidate, in Rodent Pain Models
Nava Zisapel, Ph.D., Professor, Neurobiology, Faculty of Life Sciences, Tel Aviv University
Neu-P12 is a new non-COX inhibiting drug candidate in development for pain. We used three rodent models of pain to investigate the antinociceptive potential of this compound. Neu-P12 demonstrates significant does-dependent antinociceptive effects in a number of rodent pain models of neurogenic, inflammatory and neuropathic pain.

3:35 Grand Opening Refreshment Break in the Exhibit Hall

4:15 PLENARY KEYNOTE PANEL
See Page 2 for Details.

5:45 Happy Hour in the Exhibit Hall

6:45 End of Day

WEDNESDAY, JUNE 16

7:30 am Continental Breakfast Breakout Discussions
See Page 4 for Details.

Novel Targets, Novel Approaches

8:30 Chairperson's Remarks
Lindsay H. Burns, Director, Pre-Clinical Research, Pain Therapeutics, Inc.

8:40 The Discovery of a Novel Series of Tetrahydroisoquinolines as Potent TRPM8 Antagonists
Nuria A. Tamayo, Ph.D., Principal Scientist, Small Molecule Drug Discovery, Amgen, Inc.

9:10 Antibodies for Pain
Richard Torres, Ph.D., Senior Staff Scientist, Pain Therapeutics, Regeneron Pharmaceuticals, Inc.

9:40 Cellular Basis of Itch Sensation
Zhou-Feng Chen, Ph.D., Associate Professor, Washington University Pain Center, Departments of Anesthesiology, Psychiatry & Developmental Biology, Washington University School of Medicine

10:10 Networking Coffee Break, Poster and Exhibit Viewing

10:50 Filamin A: A Novel Target in Treating Pain
Lindsay H. Burns, Director, Pre-Clinical Research, Pain Therapeutics, Inc.

11:10 EXPERT PANEL: Novel Approaches to Drug Development and Study Design in Pain Programs

- Challenges in pain clinical development including predictive value of *in vivo* pre-clinical studies and failed trials
- Perspectives on conduct of smaller and more efficient proof-of-concept studies in pain
- Evaluating full potential of compounds across pain indications

Panelists:
Ramana Sonty, Ph.D., Director, Neuroscience Program, Wyeth Pharmaceuticals
Hong Wan, Ph.D., Director, Translational Medicine, Pfizer, Inc.
Mark R. Bowlby, Ph.D., Director, Pain & Migraine, Merck Research Laboratories
John T. Farrar, M.D. ,M.S.C.E., Ph.D., Assistant Professor & Senior Scholar, Departments of Biostatistics and Epidemiology, Neurology, and Anesthesiology, University of Pennsylvania

11:40 Xen2174: Discovery, Binding Mode and Development of a Novel Conopeptide Norepinephrine Transporter Inhibitor for Moderate to Severe Pain
Richard Lewis, Ph.D., CSO, Research & Development, Xenome Ltd.

12:00 pm KRN5500 Demonstrates Significant Reduction in Neuropathic Pain in Patients with Cancer
Linda Jett, MSN, Clinical Director, Drug Development, DARA BioSciences

12:20 End of Conference

Drug Discovery Innovation Summit

Second Annual

Successful Targeting of Alzheimer's Disease

Predictive *in vitro* Methods and *in vivo* Models for Alzheimer's Disease Targets

June 16-17

Recommended Short Courses*

Monday, June 14

9:00 am – 12:00 pm

(SC1) Reactive Metabolites in Drug Discovery and Development-A Critical Examination of the Issues

2:00 pm – 5:00 pm

(SC5) Dealing with the Blood-Brain Barrier

**Separate Registration Required; Please See Page 3 for Details.*

WEDNESDAY, JUNE 16

12:30 pm Registration

Building a Better Mouse: Alzheimer's Disease Animal Models

1:55 Chairperson's Opening Remarks
Timothy A. Esbenshade, Senior Group Leader, Associate Fellow, Neuroscience Research, Abbott Laboratories

2:00 Contributions of APP Intracellular Domain (AICD) to Alzheimer's Disease: The Evidence and the Mechanism
Sanjay W. Pimplikar, Ph.D., Assistant Staff, Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation

2:30 Dysregulation of Histone Acetylation in Alzheimer's Disease
Ottavio Arancio, M.D., Ph.D., Associate Professor, Department of Pathology and Cell Biology & The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University

3:00 Inhibition of APP Processing with HPP854, a Novel, Selective, Orally Active Inhibitor of Beta Amyloid Cleavage Enzyme (BACE), Results in Therapeutic Benefit in an Animal Model of Alzheimer's Disease
Matthew Kostura, Ph.D., Vice President, Biology, Trans Tech Pharma

3:30 Networking Refreshment Break, Poster and Exhibit Viewing

4:30 Animal Models of Neurological Disorders in Drug Discovery Research
Jean-Cosme Dodart, Ph.D., Director, Mouse NeuroBehavior Core, Harvard NeuroDiscovery Center, Harvard Medical School

5:00 Recreating Full AD-like Disease Progression in Mouse Models
Carol A. Colton, Ph.D., Professor, Neurology, Duke University

5:30 KEYNOTE ADDRESS
Targeting Neurodegeneration: Genes, Biomarkers and Therapies
Eric R. Siemers, M.D., Medical Director, Alzheimer's Disease Research, Eli Lilly & Co.

6:00 End of Day

THURSDAY, JUNE 17

7:30-8:20 am BREAKOUT DISCUSSION: Challenging Hypotheses for Alzheimer's Disease

Small working groups will challenge current hypotheses for targeting Alzheimer's disease, including addressing the following questions:

- What data do we need to disprove the amyloid hypothesis?
- Is there room for more than one right answer?

Moderator: William J. Ray, Ph.D., Director, Neurology, Merck Research Laboratories

CNS Imaging in Pre-Clinical Development

8:20 Chairperson's Remarks
Cornelia Reininger, M.D., Ph.D., Director, Global Clinical Development, Bayer Health Care Pharmaceuticals

8:30 Imaging of Alzheimer's Disease: a Drug Discovery and Development Perspective
Thomas Krucker, Ph.D., Head, Molecular Imaging, Novartis Institute for Biomedical Research

9:00 The Role of Amyloid Tracers in Disease Detection in AD, Early Identification and Pre-Selection for Therapy
Cornelia Reininger, M.D., Ph.D., Director, Global Clinical Development, Bayer Health Care Pharmaceuticals

9:30 Pre-Clinical Imaging of Amyloid-β Plaque: In Search of an Animal Model
Cyrille Sur, Ph.D., Director, Molecular Imaging, Merck Research Laboratories

10:00 Networking Coffee Break, Poster and Exhibit Viewing

Drug Discovery Targets

10:40 Chairperson's Remarks
Carol A. Colton, Ph.D., Professor, Neurology, Duke University

10:45 Developing New Targets for Alzheimer's Disease Using Functional Genomics
William J. Ray, Ph.D., Director, Neurology, Merck Research Laboratories

11:15 Metabolic Targets for Alzheimer Disease
Mark A. Smith, Ph.D., Professor of Pathology, Case Western Reserve

11:45 Luncheon Presentations *(Sponsorship Opportunities Available)* **or Lunch on Your Own**

1:25 pm γ-Secretase as a Target for Alzheimer Disease Therapy: Small Molecule Development
Corinne E. Augelli-Szafran, Ph.D., Director, Laboratory of Experimental Alzheimer Drugs (LEAD), Brigham and Women's Hospital, Center for Neurologic Diseases and Harvard Medical School

1:55 α7 Nicotinic Acetylcholine Receptor Agonists: Therapeutic Promise for Symptomatic and Disease Modifying Efficacy in Alzheimer's Disease
Timothy A. Esbenshade, Ph.D., Senior Group Leader, Associate Fellow, Neuroscience Research, Abbott Laboratories

2:25 Ice Cream Refreshment Break in the Exhibit Hall

3:05 EXPERT PANEL

Bridging the Gap Between Alzheimer's Disease Research and Drug Discovery: What are the Key Features for Moving a Compound Forward?
Moderator: Corinne E. Augelli-Szafran, Ph.D., Director, LEAD, Brigham and Women's Hospital, Center for Neurologic Diseases and Harvard Medical School

Panelists:

William J. Ray, Ph.D., Director, Neurology, Merck Research Laboratories

Mark A. Smith, Ph.D., Professor of Pathology, Case Western Reserve

Carol A. Colton, Ph.D., Professor, Neurology, Duke University

3:35 Development of Novel HDAC Inhibitors for Neurodegenerative Diseases
Holger Patzke, Ph.D., Associate Director, EnVivo Pharmaceuticals

4:05 Targeting Glia-Neuron Interactions that Result in Synaptic Dysfunction as a Drug Discovery Strategy for Alzheimer's Disease
Linda VanEldik, Ph.D., Director, Sanders-Brown Center on Aging, and Professor, Department of Anatomy and Neurobiology, University of Kentucky, Lexington KY

4:35 End of Conference

Sponsoring Publications:

Fourth Annual

Monitoring Cardiotoxicity and Drug Safety

Defining Early, Efficient and Effective Ways for Predicting Drug Safety

June 15-16

Recommended Short Courses*

Monday, June 14

9:00 am – 12:00 pm

(SC3) Translating Safety Biomarkers from the Lab to the Clinic

(SC4) Use of Stem Cells for Safety Screening

2:00 pm – 5:00 pm

(SC6) Addressing Safety Concerns for Biological Drugs

(SC8) Mechanistic Insights into Cardiotoxicity

**Separate Registration Required; Please See Page 3 for Details.*

TUESDAY, JUNE, 15

7:15 am Registration and Morning Coffee

Translating Pre-Clinical Predictions to Clinical Safety

8:15 Chairperson's Opening Remarks
Gary Gintant, Ph.D., Senior Group Leader, Department of Integrative Pharmacology, Global Pharmaceutical Research & Development, Abbott Laboratories

8:25 Pre-Clinical Cardiac Safety: Moving Ahead of hERG
Gary Gintant, Ph.D., Senior Group Leader, Department of Integrative Pharmacology, Global Pharmaceutical Research & Development, Abbott Laboratories

8:55 Talk Title to be Announced
Speaker to be Announced

9:25 *In vitro-in vivo* Correlation of Cardiotoxicity For a Small Molecule cMET Inhibitor
Amy Kim, Ph.D., Senior Scientist, Genentech, Inc.

9:55 Networking Coffee Break

Novel *in vitro* Approaches for Assessing Cardiac Liabilities

10:25 Enriched Human Cardiomyocytes from Embryonic Stem Cells for Drug Discovery and Safety Pharmacology
*William Sun, Ph.D., Group Leader, Stem Cell Technology, Experimental Therapeutics Centre, A*STAR*

10:55 High Content Cardiotoxicity Profiling with Engineered Heart Tissues: Mitochondrial Toxicity and Genomic Influences
Tetsuro Wakatsuki, Ph.D., Assistant Professor of Physiology, Biotechnology and Bioengineering Center, Medical College of Wisconsin

11:25 Evolution of *in vitro* Strategies for Cardiotoxicity Assessment
Adam W. Hendricson, Ph.D., Research Investigator, Lead Evaluation and Ion Channels, Bristol-Myers Squibb Co.

11:55 Luncheon Presentation Sponsored by ELSEVIER
Using Data Sources, Organization, and Longitudinal Views of Preclinical, Clinical and Post-Market Observations to Better Inform Drug Development Candidates Assessments
Philip MacLaughlin, Senior Product Manager, Elsevier

12:25 Luncheon Presentation Sponsored by Meso Scale Discovery
Development of Multiplexed Biomarker Assays for Toxicity
Pankaj Oberoi, Ph.D., Director, Qualified Kit Development, Director, Scientific Services, Meso Scale Discovery

Drug-Class Associated Cardiotoxicity

1:25 pm Chairperson's Remarks
Thomas Force, M.D., Professor of Medicine and Clinical Director of the Center for Translational Medicine, Thomas Jefferson University

1:35 Understanding Cardiotoxicity of Tyrosine Kinase Inhibitors: From Clinical Outcomes to Mechanisms of Cardiotoxicity
Thomas Force, M.D., Professor of Medicine and Clinical Director of the Center for Translational Medicine, Thomas Jefferson University

2:05 Biologicals and Cardiac Toxicity Risk: Relating Toxicity to Mechanism of Action
Noël Dybdal, Ph.D., D.V.M., Associate Director, Principal Scientist, Safety Assessment, Genentech, Inc.

2:35 PANEL DISCUSSION: How Well Can We Correlate *in vitro* and *in vivo* Models to Predict Cardiotoxicity?
Moderator: Thomas Force, M.D., Professor of Medicine and Clinical Director of the Center for Translational Medicine, Thomas Jefferson University

3:05 Presentations Sponsored by QUINTILES
New Regulatory Landscapes for the Prospective Exclusion of Unacceptable Cardiovascular Risk: FDA and EMA Documents addressing the Development of New Antidiabetic Drugs for Type 2 Diabetes Mellitus
J. Rick Turner, Ph.D., Senior Scientific Director, Cardiac Safety Services, Quintiles

3:35 Grand Opening Refreshment Break in the Exhibit Hall

4:15 PLENARY KEYNOTE PANEL
See Page 2 for Details.

5:45 Happy Hour in the Exhibit Hall

6:45 End of Day

WEDNESDAY, JUNE 16

7:30 am Continental Breakfast Breakout Discussions
See Page 4 for Details.

Creative Options for Predicting Drug Safety

8:30 Chairperson's Remarks
Ernest D. Bush, Ph.D., Vice President & Research Director , Cambridge Healthtech Associates

8:40 ASAT: The Netherlands Program to Develop Alternatives to Animal Testing for Drug Safety
Michael Liebman, Ph.D., President & Managing Director, Management, Strategic Medicine, Inc.

9:10 Moving the Safety Elephant: The Challenges in Getting From The Good Idea to Business As Usual
David Cook, Ph.D., Associate Director, Pharmacology and Toxcicology, Astra Zeneca R&D

9:40 Developing Cell Models and Assays with Improved Predictivity for Drug Toxicity Testing Sponsored by GE Healthcare
Stephen Minger, Ph.D., Head of R&D Cell Technologies, GE Healthcare

9:55 Presentation Sponsored by caprotec
Does Capture Compound Mass Spectrometry (CCMS) Elucidate Drug Actions?
Friedrich Kroll, Ph.D., Head, Medicinal Chemistry, caprotec bioanalytics GmbH

10:10 Networking Coffee Break, Poster and Exhibit Viewing

10:50 EXPERT PANEL: Casting the Right Safety Net: Exploring Creative Options for Predicting Drug Safety
Panelists:

David Cook, Ph.D., Associate Director, Pharmacology and Toxcicology, Astra Zeneca R&D

Michael Liebman, Ph.D., President/Managing Director, Management, Strategic Medicine, Inc.

Paul Watkins, M.D., Director, Hamner-UNC Institute for Drug Safety Sciences, University of North Carolina at Chapel Hill

Shama M. Kajiji, Ph.D., MBA, Director, Pipeline and Portfolio Management, Merck & Co.

Peggy Guzzie-Peck, Ph.D., DABT, Vice President, Head of Toxicology, Pathology & LAM, Johnson & Johnson, Pharma R&D

Stefan Platz, Ph.D., D.V.M., Head of Toxicology/Pathology, F. Hoffmann-La Roche Ltd.

12:20 pm New Systems for High-Throughput Cell Analysis and for Analysis of Beating Cardiomyocytes Sponsored by Roche
Manfred Watzele, Ph.D., Director R&D, Roche Diagnostics GmbH
Yama A. Abassi, Senior Director of Assay Development and Cell Biology, ACEA Biosciences

1:20 pm End of Conference

Sponsored by DSEC

Inaugural

New Tools for Detecting Nephrotoxicity

Defining Early, Efficient and Effective Ways for Predicting Drug Safety

June 15-16

Recommended Short Courses*

Monday, June 14

9:00 am – 12:00 pm

(SC3) Translating Safety Biomarkers from the Lab to the Clinic

(SC4) Use of Stem Cells for Safety Screening

2:00 pm – 5:00 pm

(SC6) Addressing Safety Concerns for Biological Drugs

(SC8) Mechanistic Insights into Cardiotoxicity

**Separate Registration Required; Please See Page 3 for Details.*

TUESDAY, JUNE, 15

7:00 am Registration and Morning Coffee

Validating Biomarkers for Renal Injury

8:15 Chairperson's Opening Remarks
Stephen Furlong, Ph.D., Safety Science Lead, U.S. Patient Safety, AstraZeneca

8:25 The Damaged Nephron Defends the Urinary System by Delivering NGAL
Jonathan M. Barasch, M.D., Ph.D., Associate Professor, Medicine, Anatomy and Cell Biology, Columbia University Medical Center

8:55 NGAL as a Biomarker of Acute Kidney Injury and Nephrotoxicity
Prasad Devarajan, M.D., Professor of Pediatrics and Developmental Biology, University of Cincinnati College of Medicine

9:25 Approaches to Regulatory Qualification of Safety Biomarkers
Jonathan A. Phillips, Ph.D., Senior Scientist, Integrative Toxicology, Boehringer-Ingelheim Pharmaceuticals, Inc.

9:55 Networking Coffee Break

10:25 Practical Considerations for Introducing New Safety Biomarkers into Clinical Trials
Stephen Furlong, Ph.D., Safety Science Lead, U.S. Patient Safety, AstraZeneca

10:55 KEYNOTE ADDRESS

Biomarkers of Nephrotoxicity: Uses and Challenges in Pre-Clinical and Clinical Studies
Joseph Bonventre, Ph.D., Professor of Medicine, Harvard Medical School; Chief, Renal Division, Brigham and Women's Hospital

11:25 PANEL DISCUSSION: How Succesful Will Biomarkers be in Predicting Renal Injury?
Moderator: Stephen Furlong, Ph.D., Safety Science Lead, U.S. Patient Safety, AstraZeneca

11:55 Luncheon Presentations *(Sponsorship Opportunities Available)* **or Lunch on Your Own**

Tools for Detecting and Imaging Renal Injury

1:25 pm Chairperson's Remarks
Bruce A. Molitoris, M.D., Director, Division of Nephrology and Professor of Medicine, Indiana University

1:35 Utilizing 2-Photon Fluorescent Microscopy to Understand Nephrotoxicity and Hepatotoxicity
Bruce A. Molitoris, M.D., Director, Division of Nephrology and Professor of Medicine, Indiana University

2:05 Kidney Biopsy Diagnosis of Diseases Caused by Nephrotoxic Drugs
Andrew M. Herzenberg, M.D., FRCPC, Assistant Professor, Pathology, Consultant Nephropathologist, University Health Network and University of Toronto

2:35 Renal Complications of Tyrosine Kinase Inhibitors
Ilya Glezerman, M.D., Assistant Attending Physician, Renal Service, Memorial Hospital for Cancer and Allied Diseases

3:05 ROX and BOX: New Tools for Detecting Patient Injury and Drug Toxicity *Sponsored by* solmedx
Sam Sofer, Ph.D., PE, President, solmedx

3:35 Grand Opening Refreshment Break in the Exhibit Hall

4:15 PLENARY KEYNOTE PANEL
See Page 2 for Details.

5:45 Happy Hour in the Exhibit Hall

6:45 End of Day

WEDNESDAY, JUNE 16

7:30 am Continental Breakfast Breakout Discussions
See Page 4 for Details.

Creative Options for Predicting Drug Safety

Shared Session with Monitoring Cardiotoxicity and Drug Safety

8:30 Chairperson's Remarks
Ernest D. Bush, Ph.D., Vice President & Research Director , Cambridge Healthtech Associates

8:40 ASAT: The Netherlands Program to Develop Alternatives to Animal Testing for Drug Safety
Michael Liebman, Ph.D., President & Managing Director, Management, Strategic Medicine, Inc.

9:10 Moving the Safety Elephant: The Challenges in Getting From The Good Idea to Business As Usual
David Cook, Ph.D., Associate Director, Pharmacology and Toxcicology, Astra Zeneca R&D

9:40 Developing Cell Models and Assays with Improved Predictivity for Drug Toxicity Testing *Sponsored by* GE Healthcare
Stephen Minger, Ph.D., Head of R&D Cell Technologies, GE Healthcare

10:10 Networking Coffee Break, Poster and Exhibit Viewing

10:50 EXPERT PANEL: Casting the Right Safety Net: Exploring Creative Options for Predicting Drug Safety
Panelists:

David Cook, Ph.D., Associate Director, Pharmacology and Toxcicology, Astra Zeneca R&D

Michael Liebman, Ph.D., President/Managing Director, Management, Strategic Medicine, Inc.

Paul Watkins, M.D., Director, Hamner-UNC Institute for Drug Safety Sciences, University of North Carolina at Chapel Hill

Shama M. Kajiji, Ph.D., MBA, Director, Pipeline and Portfolio Management, Merck & Co.

Peggy Guzzie-Peck, Ph.D., DABT, Vice President, Head of Toxicology, Pathology & LAM, Johnson & Johnson, Pharma R&D

Stefan Platz, Ph.D., D.V.M., Head of Toxicology/Pathology, F. Hoffmann-La Roche Ltd.

12:20 pm Label Free, High Content Cellular Analysis for the Assessment of Compound-Induced Hepatic and Cardiomyocyte Cytotoxicity *Sponsored by* Roche
Manfred Watzele, Ph.D., Director R&D, Roche Diagnostics GmbH
Kyle Kolaja, Ph.D., Director, Early Safety Assessment, Department of Nonclinical Safety, Hoffman-LaRoche

1:20 pm End of Confer

Sponsored by D-S-E-C

Third Annual

Early Assessments for Predicting Hepatotoxicity

Defining Early, Efficient and Effective Ways for Predicting Drug Safety

June 16-17

Recommended Short Courses*

Monday, June 14

9:00 am – 12:00 pm

(SC3) Translating Safety Biomarkers from the Lab to the Clinic

(SC4) Use of Stem Cells for Safety Screening

2:00 pm – 5:00 pm

(SC6) Addressing Safety Concerns for Biological Drugs

(SC8) Mechanistic Insights into Cardiotoxicity

Wednesday, June 16

6:00 pm – 9:00 pm *(Dinner will be served)*

(SC9) Mechanistic Insights into Hepatotoxicity

**Separate Registration Required; Please See Page 3 for Details.*

WEDNESDAY, JUNE 16

12:30 pm Registration

Tackling Idiosyncratic Hepatotoxicity

1:55 Chairperson's Opening Remarks
Arie Regev, M.D., Hepatology Consultant and Chair, Liver and GI Safety Committee, Global Patient Safety, Eli Lilly and Company

2:00 Early Prediction of Drug-Induced Hepatotoxicity: Where are We Now and Where are We Going?
Arie Regev, M.D., Hepatology Consultant and Chair, Liver Safety Committee, Global Patient Safety, Eli Lilly & Co.

2:30 Better Prediction of Idiosyncratic Hepatotoxicity in Pre-Clinical Species Using a Multiple -Omics Approach
William Salminen, Ph.D.., DABT, Director, Center for Hepatotoxicity, U.S. FDA National Center for Toxicological Research

3:00-3:15 Multiplex Evaluation of Mitochondrial Toxicity *Sponsored by*
Wei Zheng, M.S. Ph.D., Immunoassay Team Lead, Research & Development, Merck KGaA, EMD Chemicals (North America)

3:30 Networking Refreshment Break, Poster and Exhibit Viewing

4:30 KEYNOTE ADDRESS

New Approaches to Understand and Predict Idiosyncratic Hepatotoxicity
Paul B. Watkins, M.D., Director, Hamner-UNC Institute for Drug Safety Sciences, Verne S. Caviness Distinguished Professor of Medicine, University of North Carolina at Chapel Hill

5:00 PANEL DISCUSSION: Early Prediction of Idiosyncratic DILI: What is the Forecast for This Decade and What Should Drug Makers Do Today?
Moderator: Arie Regev, M.D., Hepatology Consultant and Chair, Liver and GI Safety Committee, Global Patient Safety, Eli Lilly and Company

5:30 End of Day

THURSDAY, JUNE 17

Unraveling Mechanisms Underlying Hepatotoxicity

8:20 am Chairperson's Remarks
Yvonne Will, Ph.D., Associate Research Fellow, Compound Safety Prediction, Pfizer Global R&D

8:30 Transcriptional and Signaling Regulation of Hepatic ABCC Genes by Hepatotoxicant Treatment
José E. Manautou, Ph.D., Associate Professor of Toxicology, Department of Pharmaceutical Sciences, University of Connecticut

9:00 Probing Mechanisms of Inter-Individual Susceptibility to Toxicants with Population-Based Experimental Approaches
Ivan Rusyn, M.D., Ph.D., Associate Professor of Environmental Science and Engineering, University of North Carolina

9:30 Mitochondrial Toxicity in Drug-Induced Liver Injury: Pre-Clinical Screening Strategy
Yvonne Will, Ph.D., Associate Research Fellow, Compound Safety Prediction, Pfizer Global R&D

10:00 Networking Coffee Break, Poster and Exhibit Viewing

10:45 Metabolism-Mediated Hepatotoxicity: Mechanisms and Predictions
Jan Wahlstrom, Ph.D., Senior Scientist, Pharmacokinetics and Drug Metabolism, Amgen, Inc.

11:15 *In vitro-in vivo* Correlations and Pharmacokinetic Drivers of Hepatotoxicity with Small Molecule Kinase Inhibitors
Dolo Diaz, Ph.D., DABT, Scientist, Investigative Safety Assessment, Genentech, Inc.

11:45 Luncheon Presentations *Sponsored by* MILLIPORE
Cell Based Assays for Lead Discovery
Jeff Till, Ph.D., Marketing Director, Drug Discovery, Millipore

New Assays and Markers for Predicting Hepatotoxicity

1:15 pm Chairperson's Remarks
Eric Blomme, D.V.M., Ph.D., D.A.C.V.P., Senior Project Leader, Abbott Laboratories

1:25 Quantitative Liver-Specific Blood Protein Fingerprint: A Signature for Hepatotoxicity
Zhiyuan Hu, Ph.D., Research Scientist, Institute for Systems Biology

1:55 *In Vitro* Prediction of Hepatotoxicity
Stefan Platz, Ph.D., D.V.M., Head of Toxicology/Pathology, F. Hoffmann-La Roche Ltd.

2:25 Ice Cream Refreshment Break in the Exhibit Hall

3:05 Sandwich-Cultured Hepatocytes: An *in vitro* Tool to Predict Hepatic Exposure of Drugs/Generated Metabolites and Hepatotoxicity
Kim L.R. Brouwer, Pharm.D., Ph.D., Chair, Division of Pharmacotherapy and Experimental Therapeutics, The University of North Carolina at Chapel Hill

3:35 Strategic Use of High-Content Technologies to Predict and Characterize Hepatotoxicity
Eric Blomme, D.V.M., Ph.D., D.A.C.V.P., Senior Project Leader, Abbott Laboratories

4:05 PANEL DISCUSSION: Effective Evaluation and Utilization of Tools for Predicting Hepatotoxicity
Moderator: Eric Blomme, D.V.M., Ph.D., D.A.C.V.P., Senior Project Leader, Abbott Laboratories

4:35 End of Conference

Reasons You Should Share Your Research at this conference:

- **Your poster will be exposed to our international delegation**
- **Receive $50 off your registration**
- **Your poster abstract will be published in our conference materials**
- **Your research will be seen by leaders from top pharmaceutical, biotech, academic and government institutes**

Poster Deadline is April 30, 2010



Sixth Annual

Evaluating Novel Technologies for Cell Based Screening

Better Tools for Predicting Leads in Drug Discovery

June 15-16

Recommended Short Courses*

Monday, June 14

9:00 am – 12:00 pm

(SC1) Reactive Metabolites in Drug Discovery and Development-A Critical Examination of the Issues

2:00 pm – 5:00 pm

(SC5) Dealing with the Blood-Brain Barrier

**Separate Registration Required; Please See Page 3 for Details.*

TUESDAY, JUNE, 15

7:15 am Registration and Morning Coffee

Miniaturization: The How and Why of Making Assays Smaller

8:15 Chairperson's Opening Remarks
Daniel G. Sipes, Director, Advanced Automation Technologies, Genomics Institute of the Novartis Research Foundation

8:25 Cell-Based Assay Miniaturization and Automation at GNF: Screening and More
Daniel G. Sipes, Director, Advanced Automation Technologies, Genomics Institute of the Novartis Research Foundation

8:55 Novel Methodologies and Technologies for Cell Based Screening at the Nano-Scale
Anthony Davies, Ph.D., Director, Trinity HCA, Clinical Medicine, Trinity College Dublin

9:25 Ultraminiaturization for High Throughput Biotechnology
Scott Diamond, Ph.D., Founding Director, Penn Center for Molecular Discovery, E. Humphrey Chair of Chemical and Biomolecular Engineering, University of Pennsylvania

9:55 Networking Coffee Break

10:25 Applying HTS Technologies Toward the Rapid Biological Characterization of Small Molecules.
Fred King, Ph.D., Research Investigator, The Novartis Institute of Biomedical Research

10:55 Doing More With Less: Advances in Miniaturization for uHTS
Eric Johnson, Ph.D., Sr. Rsch.Fellow, Automated Biotechnology, Merck Research Laboratories

11:25 A 3-D Cell Culture Microarray System for Early Toxicity Screening
David Rozzell, Ph.D., President and CEO, Solidus Biosciences, Inc.

11:55 Luncheon Presentation I *Sponsored by* applied biosystems part of life technologies

Characterizing Protein-Protein Interactions in Cell Lysates Using Proximity Ligation Assay
Kazuya Machida, Ph.D., MD, Genetics and Developmental Biology, University of Connecticut Health Center

12:25 pm Luncheon Presentation II *Sponsored by* attana

Kinetics on Cells-Bridging the Gap between Traditional Biosensor and Cell Based Assay
Camilla Käck, Ph.D., Research Scientist, Attana

Is Label-Free Right For Me?

1:25 Chairperson's Remarks
Clay Scott, Ph.D., Associate Director, Lead Generation, AstraZeneca Pharmaceuticals

1:35 Orthogonal Compound Differentiation: Where do Label-Free technologies have the greatest impact?
Matthew Todd, Ph.D., Research Fellow, Team Leader, Lead Generation Biology, Johnson & Johnson, PR&D

2:05 Problems and Promise of Cell-Based Assays in Compound Identification
Charles Lunn, Ph.D., Research Fellow, New Lead Discovery, Merck Research Laboratories

2:35 Comparing Impedance- and Optical-Based Biosensors for Use in GPCR Drug Discovery
Clay Scott, Ph.D., Associate Director, Lead Generation, AstraZeneca Pharmaceuticals

3:05 Presentation *Sponsored by* Molecular Devices

The CellKey® System. A Superior Solution for Gαi-Coupled and Gαs-Coupled GPCR Analysis
Ryan McGuinness, Senior Application Scientist, Molecular Devices Corporation

3:20 Sponsored Presentation *(Opportunity Available)*

3:35 Grand Opening Refreshment Break in the Exhibit Hall

4:15 PLENARY KEYNOTE PANEL
See Page 2 for Details.

5:45 Happy Hour in the Exhibit Hall

6:45 End of Day

WEDNESDAY, JUNE 16

7:30 am Continental Breakfast Breakout Discussions
See Page 4 for Details.

Stem and Primary Cells as Reagents

8:30 Chairperson's Remarks
Wei Zheng, Ph.D., Group Leader, NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health

8:40 Identification of Chemical Probes to Interrogate Complex Biology Using Integrated Biological Screening and Chemistry
Michelle Palmer, Ph.D., Director, Screening, Chemical Biology Platform, Broad Institute of Harvard and MIT

9:10 Utilization of Primary Cells for Phenotypic Screening in Hit Identification and Compound Profiling
Angela X. Dunne, B.Sc., M.Sc., Principal Scientist, GlaxoSmithKline

9:40 Application of Primary and Stem Cells as the Model System for Drug Screen
Wei Zheng, Ph.D., Group Leader, NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health

10:10 Networking Coffee Break, Poster and Exhibit Viewing

Beyond Test Tubes: High Throughput Flow Cytometry

10:45 Chairperson's Remarks
Larry A. Sklar, Ph.D., Distinguished Regents Professor of Pathology; Associate Director of Basic Research, University of New Mexico Cancer Center; Director, University of New Mexico Center for Molecular Discovery

10:50 Cell-Based Screening by High Throughput Flow Cytometry
Larry A. Sklar, Ph.D., Distinguished Regents Prof. of Pathology; Associate Director of Basic Rsch., Univ.. New Mexico Cancer Ctr. Director, Univ. of New Mexico Center for Molecular Discovery

11:20 Polyplexed High Throughput Protein-Interaction Assays
Richard R. Neubig, M.D., Ph.D., Professor of Pharmacology; Associate Professor of Internal Medicine; Biophysics Research Division - Associated Faculty Medicinal Chemistry IDP; Center for Chemical Genomics, Associate Director, University of Michigan

12:00 PANEL DISCUSSION: Collaborating with Academic Screening Centers
Moderator:

Michele Palmer, Ph.D., Director, Chemical Biology Platform, Broad Institute of Harvard and MIT

Panelists:

Peter Hodder, Ph.D., Senior Director, Lead Identification, Translational Research Institute, The Scripps Research Institute

Larry A. Sklar, Ph.D., Distinguished Regents Prof. of Pathology; Associate Director of Basic Rsch., Univ.. New Mexico Cancer Ctr. Director, Univ. of New Mexico Center for Molecular Discovery

Chahrzad Montrose-Rafizadeh, Ph.D., Senior Research Advisor, Eli Lilly

12:30 pm End of Conference

Inaugural

Integrating *in vivo* Molecular Imaging in Drug Discovery & Development

Advancing Projects by Leveraging Cross Functional Teams, Academic Collaborations and Technology Advancements

June 16-17

Recommended Short Courses*

Monday, June 14

9:00 am – 12:00 pm

(SC1) Reactive Metabolites in Drug Discovery and Development-A Critical Examination of the Issues

2:00 pm – 5:00 pm

(SC5) Dealing with the Blood-Brain Barrier

**Separate Registration Required; Please See Page 3 for Details.*

WEDNESDAY, JUNE 16

12:30 pm Registration

KEYNOTE SESSION

in vivo Imaging—Where Is It Having The Biggest Impact In Drug Development?

1:55 Chairperson's Opening Remarks
Susanta Sarkar, Ph.D., Director, Clinical Imaging, Medicines Development, Oncology R&D, GlaxoSmithKline

2:00 Molecular Imaging Approaches: How can it Help Drug Discovery and Development?
Susanta Sarkar, Ph.D., Director, Clinical Imaging, Medicines Development, Oncology R&D , GlaxoSmithKline

2:30

Platform Imaging Biomakers—Applications across Pre-Clinical Drug Discovery with a Focus on Neuroscience, Oncology, Cardiovascular and Future Horizons
Thomas Bocan, Ph.D., Senior Director & Head, BioImaging Center, Pfizer Global Research & Development, Pfizer, Inc.

3:00 The Imaging Probe Development Center at NIH: Novel Imaging Agents for Biomedical R&D and Translational Medicine
Gary L. Griffiths, Ph.D., Director, Imaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health

3:30 Networking Refreshment Break, Poster and Exhibit Viewing

4:30 Role for *in vivo* Imaging in the Development of Companion Diagnostics & Advancement of Drug Discovery
Francis Kalush, Ph.D., Network Leader, Diagnostics, Office of the Center Director, Center for Devices and Radiological Health, FDA

5:00

Novel PET Tracers as Translational Tools in Drug Discovery and Development
Dennis McCarthy, Ph.D., Director, Early Development, AstraZeneca R&D

5:30 End of Day

THURSDAY, JUNE 17

Utilizing CNS Imaging in Pre-Clinical Development

(Shared Session With Successful Targeting of Alzheimer's Disease)

8:20 Chairperson's Remarks
Cornelia Reininger, M.D., Ph.D., Director, Global Clinical Development, Bayer Healthcare Pharmaceuticals

8:30 Imaging of Alzheimer's Disease: A Drug Discovery and Development Perspective
Thomas Krucker, Ph.D., Head, Molecular Imaging, Global Imaging Group, Novartis Institutes for Biomedical Research, Inc. (NIBRI), USA

9:00 The Role of Amyloid Tracers in Disease Detection in AD, Early Identification and Pre-Selection for Therapy
Cornelia Reininger, M.D., Ph.D., Director, Global Clinical Development, Bayer Healthcare Pharmaceuticals

9:30 Pre-Clinical Imaging of Amyloid-BETA Plaque: In Search of an Animal Model
Cyrille Sur, Ph.D., Director, Imaging, Merck Research Laboratories

10:00 Networking Coffee Break, Poster and Exhibit Viewing

Imaging & Oncology Drug Development—Tumor Targeting

10:45 Challenges to the Application of Imaging to the Therapeutic Drug Development Pipeline
James Tatum, M.D., Associate Director, Division of Cancer Treatment and Diagnosis, NCI/NIH

11:15 Target-Cell Specific "Smart" Imaging Probes for Super-Specific Cancer Cell Detection
Hisataka Kobayashi, M.D., Ph.D., Chief Scientist, Molecular Imaging Program, NCI/NIH

11:45 Luncheon Presentation *Sponsored by*
***In Vivo* Biophotonic Imaging – Applications within the Cancer Setting**
Christine L. Olsson, Ph.D., Commercialization Scientific Director, Taconic

Impact on Drug Development Case Studies

1:15 pm Chairperson's Remarks
Essa Hu, Ph.D., Principal Scientist, Medicinal Chemistry, Amgen

1:25 Using Imaging Techniques to Characterize Novel Histamine H3 Antagonists
Michael A. Letavic, Ph.D., Research Fellow, Neuroscience, Johnson & Johnson PRD, L.L.C.

1:55 Molecular Imaging of Cancer: Prediction and Early Detection of Therapeutic Response
Jerry D. Glickson, Ph.D., Professor and Director of Molecular Imaging, Department of Radiology, University of Pennsylvania School of Medicine

2:25 Ice Cream Refreshment Break in the Exhibit Hall

Imaging RNAi and Biologics

3:05 *in vivo* Imaging after Non-Viral RNA Gene Delivery to the Brain
James Hecker, Ph.D., M.D., Assistant Professor, Anesthesia and Critical Care, University of Pennsylvania

3:35 From Small Molecules to Biologics and Nanoparticles—(Optical) Imaging Probe Designs for Pre-Clinical Applications and their Potential Translation
Rainer Kneuer, Ph.D., Research Investigator II, Lab Head, Tracer Development, Novartis Institutes for Biomedical Research, Inc.

4:05 EXPERT PANEL: Asking the Right Biological Questions—Tailoring the Imaging Solution

Using Imaging to monitor:

- The distribution of a drug
- Expression of a target
- Drug at the site of target
- Monitoring pharmaceutical readout

Panelists:

Stacey Oppenheimer, Ph.D., Senior Scientist, Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Pfizer, Inc.

James Hecker, Ph.D., M.D., Assistant Professor, Anesthesia and Critical Care, University of Pennsylvania

4:35 End of Conference

JOIN our **LinkedIn** Group and **STAY CONNECTED!**

Sixth Annual

Pharmacology Driven Assays for GPCRs & Ion Channels

Better Screening Strategies for Current Targets

June 16-17

Recommended Short Courses*

Monday, June 14

2:00 pm – 5:00 pm

(SC5) Dealing with the Blood-Brain Barrier

Separate Registration Required; Please See Page 3 + 4 for Details.

WEDNESDAY, JUNE 16

11:00 am Registration

12:00 pm PANEL DISCUSSION:
Collaborating with Academic Screening Centers

Moderator:
Michele Palmer, Ph.D., Director, Chemical Biology Platform, Broad Institute of Harvard and MIT

Panelists:

Peter Hodder, Ph.D., Senior Director, Lead Identification, Translational Research Institute, The Scripps Research Institute

Larry A. Sklar, Ph.D., Distinguished Regents Professor of Pathology; Associate Director of Basic Research, University of New Mexico Cancer Center; Director, University of New Mexico Center for Molecular Discovery

Chahrzad Montrose-Rafizadeh, Ph.D., Senior Research Advisor, Eli Lilly

12:30 pm Lunch on Your Own

Creating Gold Standards: Novel Approaches & Technologies for Ion Channels

1:55 Chairperson's Opening Remarks
Gül Erdemli, M.D., Ph.D., Head, Ion Channel Group, Lead Finding Platform, Novartis Institute for Biomedical Research

2:00 Discovery of Potent and Selective T-Type Voltage-Gated Calcium Channel Antagonists

Victor Uebele, Ph.D., Senior Research Biologist, Depression & Circadian Disorders, Merck Research Laboratories

2:30 Automated Electrophysiology Technologies for Ion Channel Drug Discovery and Safety Profiling
Gül Erdemli, M.D., Ph.D., Head, Ion Channel Group, Lead Finding Platform, Novartis Institute for Biomedical Research

3:00 Introduction to the IonWorks Barracuda System: An Automated Electrophysiology Platform for Measuring Ligand- or Voltage-Gated Channels Simultaneously in 384 Wells
Sponsored by Molecular Devices
Karen Cook, Field Application Scientist, Molecular Devices, Inc.

3:30 Networking Refreshment Break, Poster and Exhibit Viewing

4:30 Medicinal Chemistry Studies Leading to the Discovery of CP-810,123, a Selective α7 nAChR Agonist for the Treatment of Schizophrenia
Christopher J. O'Donnell, Ph.D., Senior Director, Neuroscience Chemistry, Pfizer, Inc.

5:00 Novel Ion Channel-Based Assays for Detecting and Characterizing 7TM Receptor Modulators
Colleen Niswender, Ph.D., Research Assistant Professor, Pharmacology, Vanderbilt University

5:30 End of Day

THURSDAY, JUNE 17

Impacting GPCRs: Dimerization, Modulation and Functional Selectivity

8:20 am Chairperson's Remarks
Terry Kenakin, Ph.D., Director, Biological Reagents and Assay Development, GlaxoSmithKline R&D

8:30 The Importance of Pharmacology in New Drug Discovery with Reference to Allosteric and Functionally Selective Molecules
Terry Kenakin, Ph.D., Director, Biological Reagents and Assay Development, GlaxoSmithKline

9:00 Functionally Selective and Context-Dependent Pharmacology of GPCR Allosteric Modulators
Colleen Niswender, Ph.D., Research Assistant Professor, Pharmacology, Vanderbilt University

9:30 Precision Pharmacology: GPCR Biased Ligands Elicit Unique Signal Transduction Profiles
Scott DeWire, Ph.D., Senior Research Scientist, Co-founder, Trevena Inc.

10:00 Networking Coffee Break, Poster and Exhibit Viewing

10:45 Identification of Novel GPCR Activators: Small Molecules and Superagonists
Alan S. Kopin, M.D., Professor of Medicine, Director, Molecular Pharmacology Research Center, Tufts Medical Center, Tufts University School of Medicine

11:15 Impact of Heterodimerization of GPCRs in Drug Discovery
Lakshmi Devi, Ph.D., Professor, Pharmacology and Systems Therapeutics, Professor, Psychiatry; Mount Sinai

11:45 Luncheon Presentations *(Sponsorship Opportunities Available)* **or Lunch on Your Own**

Advances in GPCR Screening

1:15 pm Chairperson's Remarks
Lisa K. Minor, Ph.D.

1:25 BacMam: The Solution to 7TM Receptor and Ligand-Gated Ion Channel Assays
Elizabeth A. Davenport, Ph.D., Manager, Cell-Based Assay Development, Department of Biological Reagents and Assay Development, GlaxoSmithKline

1:55 Parallel Screening of Target and Anti-Target Accelerates the Hit-To-Lead Effort
Peter Hodder, Ph.D., Senior Director, Lead Identification, Translational Research Institute, The Scripps Research Institute

2:25 Ice Cream Refreshment Break in the Exhibit Hall

3:05 GPCR Assays for High Throughput and Ultra High Throughput Screening
Priya Kunapuli, Ph.D., Director, In Vitro Sciences, BRSO, Merck Research Laboratories

3:35 Application of Label-Free Assays for GPCR Targets
Hong Xin, Ph.D., Senior Scientist, Lead Generation Biology, Johnson & Johnson, PRD

4:05 High Throughput Screening Strategies for the Identification of Allosteric Modulators of 7TM Receptors
John Watson, Ph.D., Lead Investigator, Bristol-Myers Squibb

4:35 End of Conference

Sponsorship and Exhibit Information

Sponsorship Information
The World Pharmaceutical Congress presents your company with the opportunity to network with decision-makers and leading professionals from throughout the biopharmaceutical community. By participating as an Active Sponsor, your company can identify new business leads, market new technology and increase brand awareness, while positioning itself as a thought leader amongst qualified buyers.

SPONSORSHIP OPPORTUNITIES INCLUDE:

Sponsored Presentations
Speak to a captive audience about your latest technology. Sponsorship includes a 15-minute podium presentation within the scientific agenda, exhibit space, on-site branding, and access to cooperative marketing efforts by CHI.

Breakfast & Luncheon Presentations
Invite session attendees to enjoy breakfast or lunch on your company's behalf while you give your talk. Includes a 30-minute presentation and concludes with a 15-minute Q&A session.

Focus Groups
Conduct market research and gather feedback on a new product or idea from industry experts by running a focus group on-site at the World Pharmaceutical Congress. CHI will work closely with you to execute this exclusive gathering.

User Group Meetings
Co-locate your user group meeting with The World Pharmaceutical Congress. CHI will help market the event, manage logistical operations, develop the agenda, and more. CHI can handle the entirety of the meeting, or aspects of your choosing.

Other Networking and Promotional Opportunities:
- Badge Lanyards Sponsor (exclusive)
- Exhibit Hall Reception
- Hotel Room Door Hanger (1 night exclusive)
- Hotel Room Drop
- Keynote Chair Drop
- Specific Conference Chair Drop
- Padfolio Sponsor
- Refreshment Break
- Tote Bag Sponsor
- Tote Bag Insert
- Program & Exhibit Guide Sponsor (exclusive)

Invitation-Only VIP Dinner
Hand-pick your top prospects for a night of networking at a premier local venue. Sponsors will enjoy face-to-face networking in a relaxed and collaborative atmosphere. CHI will work closely with you to develop an invitation format and invitees list.

Exhibitor Information
Exhibitors at the World Pharmaceutical Congress will enjoy facilitated networking opportunities with over 400 high-level decision-makers. Speak face to face with prospective clients and showcase your latest product, service or solution.



FOR **SPONSORSHIP & EXHIBIT OPPORTUNITIES**

PLEASE CONTACT:
Suzanne Carroll
Manager, Business Development
781-972-5452 • scarroll@healthtech.com

Hotel & Travel Information

Sheraton Philadelphia City Center

17th and Race Streets
Philadelphia, PA 19103
www.Sheraton.com
Phone: 215-448-2000
Fax: 215-448-2864

Discounted Room Rate: $149 s/d
Discounted Cut-off Date: May 18, 2010

Please visit our website to make your reservations online or call the hotel directly. Identify yourself as a Cambridge Healthtech Institute conference attendee to receive the discounted room rate. Reservations made after the cut-off date or after the group room block has been filled (whichever comes first) will be accepted on a space-and-rate-availability basis. Rooms are limited, so please book early.

Flight Discounts:

To receive a 5% or greater discount on all American Airline flights please use one of the following methods:

- Call 1-800-433-1790 use Conference code 6360AD
- Go to www.aa.com enter Conference code 6360AD in promotion discount box
- Contact Wendy Levine, Great International Travel 1-800-336-5248 ext. 137

Car Rental Discounts:

Special discount rentals have been established with AVIS for this conference. Please use one of the following methods:

- Call AVIS, 800-331-1600 use our Avis Worldwide Discount (AWD) Number J868190
- Go to www.avis.com use our Avis Worldwide Discount (AWD) Number J868190

If you are driving, visit our website for information on finding nearby parking lots and the rates in and around the city.

HOW TO REGISTER:

Online: WorldPharmaCongress.com
Email: reg@healthtech.com **Phone:** 781-972-5400 **Fax:** 781-972-5425

Ninth Annual World Pharmaceutical Congress

❑ **Yes! Please register me for World Pharmaceutical Congress**

Key Code WPC F

REGISTRATION INFORMATION

❑Mr. ❑Ms. ❑Mrs. ❑Dr. ❑Prof.

Name _____
Job Title _____ Div./Dept. _____
Company _____
Address _____
City/State/Postal Code _____
Country _____
Telephone _____
How would you prefer to receive notices from CHI? Email: ❑Yes ❑No Fax: ❑Yes ❑No
Email* _____ Fax

*Email is not a mandatory field. However, by excluding your email you will not receive notification about online access to pre-conference presenter materials, conference updates, networking opportunities and requested eNewsletters.

SHORT COURSE PRICING - June 14 & 16, 2010

	Commercial	Academic, Government, Hospital-Affiliated
Short Course Only		
Single Short Course:	❑ $645	❑ $345
Two Short Courses:	❑ $945	❑ $545
Add a Short Course to your conference registration and SAVE $100		
Single Short Course:	❑ $545	❑ $245
Two Short Courses:	❑ $845	❑ $445

REQUIRED: Please select the Short Course(s) you will attend

❑ SC1 Reactive Metabolites in Drug Discovery and Development-A Critical Examination of the Issues
❑ SC2 Animal Models of Pain: Progress and Challenges
❑ SC3 Translating Safety Biomarkers from the Lab to the Clinic
❑ SC4 Use of Stem Cells for Safety Screening
❑ SC5 Dealing with the Blood-Brain Barrier
❑ SC6 Addressing Safety Concerns for Biological Drugs
❑ SC8 Mechanistic Insights into Cardiotoxicity
❑ SC9 Mechanistic Insights into Hepatotoxicity

CONFERENCE PRICING

Single Conference Pricing (Includes access to 2 conference days, excludes short courses)		
Early Registration until March 12, 2010	❑ $1,295	❑ $625
Advance Registration Deadline until April 30, 2010	❑ $1,445	❑ $695
After April 30, 2010 and on-site	❑ $1,645	❑ $795

REQUIRED - Please select the one conference you will attend

June 15-16	June 16-17
❑ Targeting Pain with Novel Therapeutics	❑ Successful Targeting of Alzheimer's Disease
❑ Monitoring Cardiotoxicity and Drug Safety	❑ Early Assessments for Predicting Hepatotoxicity
❑ New Tools for Detecting Nephrotoxicity	❑ Integrating *in vivo* Molecular Imaging in Drug Discovery and Development
❑ Evaluating Novel Technologies for Cell Based Screening	❑ Pharmacology Driven Assays for GPCRs & Ion Channels

Multiple Conference Pricing		
Early Registration Until March 12, 2010	❑$2,190	❑$865
Advance Registration Deadline until April 30, 2010	❑$2,345	❑$955
After April 30, 2010 and on-site	❑ $2,495	❑ $1,045

REQUIRED - Please select the two conferences you will attend

June 15-16	June 16-17
❑ Targeting Pain with Novel Therapeutics	❑ Successful Targeting of Alzheimer's Disease
❑ Monitoring Cardiotoxicity and Drug Safety	❑ Early Assessments for Predicting Hepatotoxicity
❑ New Tools for Detecting Nephrotoxicity	❑ Integrating *in vivo* Molecular Imaging in Drug Discovery and Development
❑ Evaluating Novel Technologies for Cell Based Screening	❑ Pharmacology Driven Assays for GPCRs & Ion Channels

☛ **REGISTER 3 - 4th IS FREE**

Individuals must register for the same conference or conference combination and submit completed registration form together for discount to apply. Please reproduce this registration form as needed.

❑ I cannot attend but would like to purchase the World Pharmaceutical Congress CD for $750 (plus shipping). Massachusetts delivery will include sales tax.

❑ Please send information on exhibiting and opportunities to present workshops.

PAYMENT INFORMATION

❑ Enclosed is a check or money order payable to Cambridge Healthtech Institute, drawn on a U.S. bank, in U.S. currency.

❑ Invoice me, but reserve my space with credit card information listed below.

Invoices unpaid two weeks prior to conference will be billed to credit card at full registration rate. Invoices must be paid in full and checks received by the deadline date to retain registration discount. If you plan to register on site, please check with CHI beforehand for space availability.

❑ Please charge: ❑ AMEX (15 digits) ❑ Visa (13-16 digits) ❑ MasterCard (16 digits)

Card # _____ Exp. date _____
Cardholder Signature _____
Cardholder's Address (if different from above) _____
City/State/Postal Code _____
Country _____

CHI Insight Pharma Reports

A series of diverse reports designed to keep life science professionals informed of the salient trends in pharmaceutical technology, business, clinical development, and therapeutic disease markets.
For a detailed list of reports, visit **InsightPharmaReports.com**, or contact Rose LaRaia, rlaraia@healthtech.com, 781-972-5444.

Barnett Educational Services

Barnett is a recognized leader in clinical education, training, and reference guides for life science professionals involved in the drug development process. For more information, visit **www.barnettinternational.com.**

Please refer to the Registration Code below:

Cambridge Healthtech Media Group

Yes! I would like to receive a FREE eNewsletter subscription to: **www.chimediagroup.com**

❑ Weekly Update The latest industry news, commentary and highlights from Bio•IT World

❑ eCliniqua Innovative management in clinical trials

❑ Pharma Services News Informatics tools and strategies driving decisions

PRESENT A POSTER AND SAVE $50

Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions.
To secure a poster board and inclusion in the conference materials, your abstract must be submitted, approved and your registration paid in full by **April 30, 2010**.
Register online, or by phone, fax or mail. Indicate that you would like to present a poster and you will receive abstract submission instructions via email.

Yes, I am interested in presenting a poster at
❑ **World Pharmaceutical Congress**
Title _____

Additional Registration Details
Each registration includes all conference sessions, posters and exhibits, food functions, and access to the conference proceedings link.

Group Discounts
Special rates are available for multiple attendees from the same organization. **Contact David Cunningham at 781-972-5472** to discuss your options and take advantage of the savings.

Handicapped Equal Access
In accordance with the ADA, Cambridge Healthtech Institute is pleased to arrange special accommodations for attendees with special needs. All requests for such assistance must be submitted in writing to CHI at least 30 days prior to the start of the meeting.

Substitution/Cancellation Policy
In the event that you need to cancel a registration, you may:

- Transfer your registration to a colleague within your organization.
- Credit your registration to another Cambridge Healthtech Institute program.
- Request a refund minus a $100 processing fee per conference.
- Request a refund minus the cost ($750) of ordering a copy of the CD.

NOTE: Cancellations will only be accepted up to two weeks prior to the conference.
Program and speakers are subject to change.

Video and or audio recording of any kind is prohibited onsite at all CHI events.